Latest FDA approvals update... Mar 16
BioXcel Therapeutics announced that it has completed its pre-NDA meeting with the FDA for BXCL501 for the acute treatment of agitation in patients with ... Nov 12
BXCL50 is indicated for the treatment of agitation associated with Delirium... Oct 27
-Advertisements-